Wednesday, February 4, 2015

Nuclea Biotechnologies Partners with BacterioScan on New Instrument

Nuclea Biotechnologies Inc. announced that it is partnering with BacterioScan inc. of St. Louis, to do the validation testing of its BacterioScan 216Dx instrument in a CLIA certified laboratory.

This collaboration will focus on antimicrobial susceptibility testing to guide the best course of antibiotic treatment for different strains of urinary tract infections.

BacterioScan focuses on the rapid detection and real-time quantification of bacteria in fluid using optical measurements. BacterioScan represents a new frontier in microbial lab technology that enables researchers to quantify bacterial concentration and growth in a liquid in under twenty minutes. Nuclea Biotechnologies Inc. headquartered in Pittsfield, Massachusetts, is developing and commercializing molecular oncology and metabolic syndrome diagnostics, with a recent expansion into infectious diseases.

The BacterioScan 216D can be used to detect and quantify bacterial concentrations that would typically fall below the detection limits of spectrophotometers.

0 Comments:

Post a Comment